

Sitagliptin / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
10.0	11.08.2025	24511-00025	Date of first issue: 21.10.2014

Section 1: Identification

Product name : Sitagliptin / Simvastatin Formulation

Manufacturer or supplier's details

Company : MSD

Address : 33 Whakatiki Street - Private Bag 908
Upper Hutt - New Zealand

Telephone : 0800 800 543

Emergency telephone number : 0800 764 766 (0800 POISON) 0800 243 622 (0800 CHEMCALL)

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

Section 2: Hazard identification**GHS Classification**

Serious eye damage/eye irritation : Category 2

Skin sensitisation : Category 1

Carcinogenicity (Inhalation) : Category 2

Specific target organ toxicity - repeated exposure : Category 2 (Liver, muscle, optic nerve, Eye)

Hazardous to the aquatic environment - chronic hazard : Category 3

GHS label elements

Hazard pictograms :



Signal word : Warning

Hazard statements : H317 May cause an allergic skin reaction.
H319 Causes serious eye irritation.

Sitagliptin / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
10.0	11.08.2025	24511-00025	Date of first issue: 21.10.2014

H351 Suspected of causing cancer if inhaled.
H373 May cause damage to organs (Liver, muscle, optic nerve, Eye) through prolonged or repeated exposure.
H412 Harmful to aquatic life with long lasting effects.

Precautionary statements

:

Prevention:

P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P261 Avoid breathing dust.
P264 Wash skin thoroughly after handling.
P272 Contaminated work clothing should not be allowed out of the workplace.
P273 Avoid release to the environment.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P302 + P352 IF ON SKIN: Wash with plenty of water.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P308 + P313 IF exposed or concerned: Get medical advice/ attention.
P333 + P313 If skin irritation or rash occurs: Get medical advice/ attention.
P337 + P313 If eye irritation persists: Get medical advice/ attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

May form explosive dust-air mixture during processing, handling or other means.

Section 3: Composition/information on ingredients

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Sitagliptin Phosphate	654671-77-9	>= 10 -< 20
Cellulose	9004-34-6	>= 1 -< 10
Starch	9005-25-8	>= 1 -< 10
Simvastatin	79902-63-9	>= 2.5 -< 10
Ascorbic acid	50-81-7	>= 1 -< 10
Titanium dioxide	13463-67-7	>= 0.1 -< 1

Sitagliptin / Simvastatin Formulation

Version 10.0	Revision Date: 11.08.2025	SDS Number: 24511-00025	Date of last issue: 06.07.2024 Date of first issue: 21.10.2014
-----------------	------------------------------	----------------------------	---

Section 4: First-aid measures

General advice	: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	: If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	: In case of contact, immediately flush skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.
If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	: May cause an allergic skin reaction. Causes serious eye irritation. Suspected of causing cancer if inhaled. May cause damage to organs through prolonged or repeated exposure.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	: Treat symptomatically and supportively.

Section 5: Fire-fighting measures

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire-fighting	: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: Carbon oxides Metal oxides Oxides of phosphorus
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Sitagliptin / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
10.0	11.08.2025	24511-00025	Date of first issue: 21.10.2014

Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment : In the event of fire, wear self-contained breathing apparatus.
for firefighters Use personal protective equipment.

Section 6: Accidental release measures

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Section 7: Handling and storage

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not get on skin or clothing.
Do not breathe dust.
Do not swallow.
Do not get in eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Minimize dust generation and accumulation.

Sitagliptin / Simvastatin Formulation

Version 10.0 Revision Date: 11.08.2025 SDS Number: 24511-00025 Date of last issue: 06.07.2024
Date of first issue: 21.10.2014

- Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures** : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Contaminated work clothing should not be allowed out of the workplace.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
- Conditions for safe storage** : Keep in properly labelled containers.
Store in accordance with the particular national regulations.
- Materials to avoid** : Do not store with the following product types:
Strong oxidizing agents

Section 8: Exposure controls/personal protection

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Sitagliptin Phosphate	654671-77-9	TWA	0.6 mg/m ³ (OEB 2)	Internal
Cellulose	9004-34-6	WES-TWA	10 mg/m ³	NZ OEL
		TWA	10 mg/m ³	ACGIH
Simvastatin	79902-63-9	TWA	25 µg/m ³ (OEB 3)	Internal
	Further information: DSEN			
		Wipe limit	250 µg/100 cm ²	Internal
Starch	9005-25-8	WES-TWA	10 mg/m ³	NZ OEL
		TWA	10 mg/m ³	ACGIH
Ascorbic acid	50-81-7	TWA	5000 µg/m ³ (OEB 1)	Internal
Titanium dioxide	13463-67-7	WES-TWA	10 mg/m ³	NZ OEL

- Engineering measures** : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
Minimize open handling.

Sitagliptin / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
10.0	11.08.2025	24511-00025	06.07.2024
			Date of first issue: 21.10.2014

Personal protective equipment

Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	:	Particulates type
Hand protection	:	
Material	:	Chemical-resistant gloves
Remarks	:	Consider double gloving.
Eye protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

Section 9: Physical and chemical properties

Appearance	:	powder
Colour	:	pink
Odour	:	No data available
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available

Sitagliptin / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
10.0	11.08.2025	24511-00025	Date of first issue: 21.10.2014

Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	Not applicable
Relative vapour density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, kinematic	:	Not applicable
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics Particle size	:	No data available

Section 10: Stability and reactivity

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

Section 11: Toxicological information

Exposure routes	:	Inhalation Skin contact
-----------------	---	----------------------------

Sitagliptin / Simvastatin Formulation

Version 10.0	Revision Date: 11.08.2025	SDS Number: 24511-00025	Date of last issue: 06.07.2024 Date of first issue: 21.10.2014
-----------------	------------------------------	----------------------------	---

Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:**Sitagliptin Phosphate:**

Acute oral toxicity	: LD50 (Rat): > 3,000 mg/kg
	LD50 (Mouse): 3,000 mg/kg

Cellulose:

Acute oral toxicity	: LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity	: LC50 (Rat): > 5.8 mg/l Exposure time: 4 h Test atmosphere: dust/mist
Acute dermal toxicity	: LD50 (Rabbit): > 2,000 mg/kg

Starch:

Acute oral toxicity	: LD50 (Rat): > 5,000 mg/kg
Acute dermal toxicity	: LD50 (Rabbit): > 2,000 mg/kg

Simvastatin:

Acute oral toxicity	: LD50 (Rat): 5,000 mg/kg
	LD50 (Mouse): 3,800 mg/kg

Ascorbic acid:

Acute oral toxicity	: LD50 (Rat): 11,900 mg/kg
---------------------	----------------------------

Titanium dioxide:

Acute oral toxicity	: LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity	: LC50 (Rat): > 6.82 mg/l Exposure time: 4 h Test atmosphere: dust/mist Assessment: The substance or mixture has no acute inhalation toxicity

Skin corrosion/irritation

Not classified based on available information.

Sitagliptin / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
10.0	11.08.2025	24511-00025	Date of first issue: 21.10.2014

Components:**Sitagliptin Phosphate:**

Species	: Rabbit
Method	: Draize Test
Result	: No skin irritation

Simvastatin:

Species	: Rabbit
Remarks	: Moderate skin irritation

Ascorbic acid:

Species	: Rabbit
Method	: OECD Test Guideline 404
Result	: No skin irritation

Titanium dioxide:

Species	: Rabbit
Result	: No skin irritation

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:**Sitagliptin Phosphate:**

Species	: Rabbit
Result	: Irritating to eyes.
Method	: Draize Test

Starch:

Species	: Rabbit
Result	: No eye irritation

Simvastatin:

Species	: Rabbit
Remarks	: slight irritation

Ascorbic acid:

Species	: Rabbit
Result	: No eye irritation
Method	: OECD Test Guideline 405

Titanium dioxide:

Species	: Rabbit
Result	: No eye irritation

Sitagliptin / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
10.0	11.08.2025	24511-00025	Date of first issue: 21.10.2014

Respiratory or skin sensitisation**Skin sensitisation**

May cause an allergic skin reaction.

Respiratory sensitisation

Not classified based on available information.

Components:**Sitagliptin Phosphate:**

Test Type	: Local lymph node assay (LLNA)
Species	: Mouse
Method	: OECD Test Guideline 429
Result	: Not a skin sensitizer.

Starch:

Test Type	: Maximisation Test
Exposure routes	: Skin contact
Species	: Guinea pig
Result	: negative

Simvastatin:

Assessment	: Probability or evidence of skin sensitisation in humans
Result	: positive

Ascorbic acid:

Test Type	: Maurer optimisation test
Exposure routes	: Skin contact
Species	: Guinea pig
Result	: negative

Titanium dioxide:

Test Type	: Local lymph node assay (LLNA)
Exposure routes	: Skin contact
Species	: Mouse
Result	: negative

Chronic toxicity**Germ cell mutagenicity**

Not classified based on available information.

Components:**Sitagliptin Phosphate:**

Genotoxicity in vitro	: Test Type: Ames test
	Result: negative
	Test Type: Chromosome aberration test in vitro

Sitagliptin / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
10.0	11.08.2025	24511-00025	Date of first issue: 21.10.2014

		Test system: Chinese hamster ovary cells Result: negative
		Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro) Test system: rat hepatocytes Result: negative
Genotoxicity in vivo	:	Test Type: Micronucleus test Species: Mouse Application Route: Oral Result: negative
Cellulose:		
Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: In vitro mammalian cell gene mutation test Result: negative
Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Ingestion Result: negative
Starch:		
Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
Simvastatin:		
Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: Alkaline elution assay Result: negative
		Test Type: Chromosomal aberration Result: negative
		Test Type: In vitro mammalian cell gene mutation test Result: negative
Genotoxicity in vivo	:	Test Type: Micronucleus test Species: Mouse Application Route: Oral Result: negative
Germ cell mutagenicity - Assessment	:	Weight of evidence does not support classification as a germ cell mutagen.

Sitagliptin / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
10.0	11.08.2025	24511-00025	Date of first issue: 21.10.2014

II

Ascorbic acid:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
	Test Type: In vitro mammalian cell gene mutation test Result: negative
	Test Type: Chromosome aberration test in vitro Result: negative
Genotoxicity in vivo	: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Ingestion Result: negative

Titanium dioxide:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
Genotoxicity in vivo	: Test Type: In vivo micronucleus test Species: Mouse Result: negative

Carcinogenicity

Suspected of causing cancer if inhaled.

Components:**Sitagliptin Phosphate:**

Species	: Mouse
Application Route	: Oral
Exposure time	: 2 Years
Result	: negative
Species	: Rat
Application Route	: oral (drinking water)
Exposure time	: 2 Years
Result	: positive
Target Organs	: Liver
Remarks	: Significant toxicity observed in testing

Carcinogenicity - Assessment	: Weight of evidence does not support classification as a carcinogen
------------------------------	--

Cellulose:

Species	: Rat
Application Route	: Ingestion
Exposure time	: 72 weeks

Sitagliptin / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
10.0	11.08.2025	24511-00025	Date of first issue: 21.10.2014

Result : negative

Simvastatin:

Species : Mouse
Application Route : Oral
Exposure time : < 92 weeks
Target Organs : Harderian gland
Tumor Type : Liver, Lungs
Remarks : The significance of these findings for humans is not certain.

Species : Rat
Application Route : Oral
Exposure time : 2 Years
Tumor Type : Liver, Thyroid
Remarks : The significance of these findings for humans is not certain.

Ascorbic acid:

Species : Mouse
Application Route : Ingestion
Exposure time : 2 Years
Result : negative

Titanium dioxide:

Species : Rat
Application Route : inhalation (dust/mist/fume)
Exposure time : 2 Years
Method : OECD Test Guideline 453
Result : positive
Remarks : The mechanism or mode of action may not be relevant in humans.

Carcinogenicity - Assessment : Limited evidence of carcinogenicity in inhalation studies with animals.

Reproductive toxicity

Not classified based on available information.

Components:**Sitagliptin Phosphate:**

Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Oral
Fertility: NOAEL Parent: 1,000 mg/kg body weight
Result: Animal testing did not show any effects on fertility.

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Teratogenicity: LOAEL: 250 mg/kg body weight

Sitagliptin / Simvastatin Formulation

Version 10.0	Revision Date: 11.08.2025	SDS Number: 24511-00025	Date of last issue: 06.07.2024 Date of first issue: 21.10.2014
-----------------	------------------------------	----------------------------	---

Result: Embryotoxic effects and adverse effects on the offspring were detected., No teratogenic effects

Test Type: Embryo-foetal development
Species: Rabbit
Teratogenicity: NOAEL: 125 mg/kg body weight
Result: No teratogenic effects

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on foetal development : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
Result: negative

Simvastatin:

Effects on fertility : Test Type: Fertility
Species: Rat, male
Application Route: Oral
Fertility: LOAEL: 25 mg/kg body weight

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Embryo-foetal toxicity: NOAEL: 25 mg/kg body weight
Result: No teratogenic effects, No adverse effects

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Oral
Embryo-foetal toxicity: NOAEL: 10 mg/kg body weight
Result: No teratogenic effects, No adverse effects

Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Embryo-foetal toxicity: LOAEL: 60 mg/kg body weight
Result: Teratogenic potential
Remarks: Based on data from similar materials

Ascorbic acid:

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Result: negative

Sitagliptin / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
10.0	11.08.2025	24511-00025	Date of first issue: 21.10.2014

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs (Liver, muscle, optic nerve, Eye) through prolonged or repeated exposure.

Components:**Simvastatin:**

Target Organs	: Liver, muscle, optic nerve, Eye
Assessment	: Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Sitagliptin Phosphate:**

Species	: Mouse
NOAEL	: 500 mg/kg
LOAEL	: 1,000 mg/kg
Application Route	: Oral
Exposure time	: > 2 yr
Target Organs	: Kidney

Species	: Rat
NOAEL	: 500 mg/kg
LOAEL	: 1,000 mg/kg
Application Route	: Oral
Exposure time	: 14 Weeks
Target Organs	: Liver, Kidney, Heart, Teeth

Species	: Dog
NOAEL	: 10 mg/kg
LOAEL	: 50 mg/kg
Application Route	: Oral
Exposure time	: 53 Weeks
Target Organs	: Central nervous system
Symptoms	: Loss of balance
Remarks	: The mechanism or mode of action may not be relevant in humans.

Species	: Dog
NOAEL	: 2 mg/kg
LOAEL	: 10 mg/kg
Application Route	: Oral
Exposure time	: 27 Weeks
Target Organs	: Skeletal muscle, Central nervous system
Symptoms	: Loss of balance
Remarks	: The mechanism or mode of action may not be relevant in humans.

Sitagliptin / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
10.0	11.08.2025	24511-00025	Date of first issue: 21.10.2014

Species	: Monkey
NOAEL	: 100 mg/kg
Application Route	: Oral
Exposure time	: 14 Weeks
Remarks	: No significant adverse effects were reported

Cellulose:

Species	: Rat
NOAEL	: $\geq 9,000$ mg/kg
Application Route	: Ingestion
Exposure time	: 90 Days

Starch:

Species	: Rat
NOAEL	: $\geq 2,000$ mg/kg
Application Route	: Skin contact
Exposure time	: 28 Days
Method	: OECD Test Guideline 410

Simvastatin:

Species	: Rat
NOAEL	: 5 mg/kg
LOAEL	: 30 mg/kg
Application Route	: Oral
Exposure time	: 14 - 104 Weeks
Target Organs	: Liver, Testis, Musculo-skeletal system, Eye

Species	: Dog
LOAEL	: 10 mg/kg
Application Route	: Oral
Exposure time	: 14 - 104 Weeks
Target Organs	: Liver, Testis, Eye

Species	: Rabbit
NOAEL	: 30 mg/kg
LOAEL	: 50 mg/kg
Application Route	: Oral
Target Organs	: Liver, Kidney

Ascorbic acid:

Species	: Rat, male
NOAEL	: $\geq 8,100$ mg/kg
Application Route	: Ingestion
Exposure time	: 13 Weeks

Titanium dioxide:

Species	: Rat
NOAEL	: 24,000 mg/kg
Application Route	: Ingestion

Sitagliptin / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
10.0	11.08.2025	24511-00025	Date of first issue: 21.10.2014

Exposure time	: 28 Days
Species	: Rat
NOAEL	: 10 mg/m ³
Application Route	: inhalation (dust/mist/fume)
Exposure time	: 2 yr

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****Sitagliptin Phosphate:**

Inhalation	: Symptoms: upper respiratory tract infection, pharyngitis, Headache
Ingestion	: Symptoms: upper respiratory tract infection, nasopharyngitis, Headache, Nausea, Abdominal pain, Diarrhoea

Simvastatin:

Skin contact	: Remarks: May produce an allergic reaction.
Ingestion	: Target Organs: Liver Symptoms: upper respiratory tract infection, Headache, Abdominal pain, constipation, Nausea Target Organs: Musculo-skeletal system

Section 12: Ecological information**Ecotoxicity****Components:****Sitagliptin Phosphate:**

Toxicity to fish	: LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): 60 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	: EC50 (Pseudokirchneriella subcapitata (green algae)): > 39 mg/l Exposure time: 96 h Method: OECD Test Guideline 201 NOEC (Pseudokirchneriella subcapitata (green algae)): 2.2 mg/l Exposure time: 96 h Method: OECD Test Guideline 201

Sitagliptin / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
10.0	11.08.2025	24511-00025	Date of first issue: 21.10.2014

Toxicity to fish (Chronic toxicity)	: NOEC (Pimephales promelas (fathead minnow)): 9.2 mg/l Exposure time: 33 d Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC (Daphnia magna (Water flea)): 9.8 mg/l Exposure time: 21 d Method: OECD Test Guideline 211
Toxicity to microorganisms	: EC50: > 150 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 NOEC: 150 mg/l Exposure time: 3 h Test Type: Respiration inhibition

Cellulose:

Toxicity to fish	: LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l Exposure time: 48 h Remarks: Based on data from similar materials
------------------	--

Simvastatin:

Toxicity to fish	: LC50 (Pimephales promelas (fathead minnow)): 2.91 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): 3.5 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	: EC50 (Pseudokirchneriella subcapitata (green algae)): > 25 mg/l Exposure time: 96 h NOEC (Pseudokirchneriella subcapitata (green algae)): 25 mg/l Exposure time: 96 h
Toxicity to microorganisms	: EC50: > 30 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 NOEC: 21 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209

Ascorbic acid:

Sitagliptin / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
10.0	11.08.2025	24511-00025	06.07.2024
			Date of first issue: 21.10.2014

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 1,020 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to microorganisms : EC50: 140 mg/l
Exposure time: 16 h
Method: DIN 38 412 Part 8

Titanium dioxide:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants : EC50 (Skeletonema costatum (marine diatom)): > 10,000 mg/l
Exposure time: 72 h

Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Method: OECD Test Guideline 209

Persistence and degradability**Components:****Sitagliptin Phosphate:**

Biodegradability : Result: not rapidly degradable
Biodegradation: 39.7 %
Exposure time: 28 d
Method: OECD Test Guideline 314

Stability in water : Hydrolysis: 50 % (401 d)
Method: OECD Test Guideline 111

Cellulose:

Biodegradability : Result: Readily biodegradable.

Simvastatin:

Biodegradability : Result: rapidly degradable

Stability in water : Hydrolysis: 50 % (3.2 d)

Ascorbic acid:

Biodegradability : Result: Readily biodegradable.
Biodegradation: 97 %
Exposure time: 5 d
Method: OECD Test Guideline 302

Sitagliptin / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
10.0	11.08.2025	24511-00025	Date of first issue: 21.10.2014

II

Bioaccumulative potential**Components:****Sitagliptin Phosphate:**

Partition coefficient: n-octanol/water	: log Pow: -0.03
--	------------------

Simvastatin:

Partition coefficient: n-octanol/water	: log Pow: > 4.07
--	-------------------

Ascorbic acid:

Partition coefficient: n-octanol/water	: log Pow: -1.85
--	------------------

Mobility in soil**Components:****Sitagliptin Phosphate:**

Distribution among environmental compartments	: log Koc: 4.37
---	-----------------

Other adverse effects

No data available

Section 13: Disposal considerations**Disposal methods**

Waste from residues	: Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging	: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

Section 14: Transport information**International Regulations****UNRTDG**

UN number	: Not applicable
Proper shipping name	: Not applicable
Class	: Not applicable
Subsidiary risk	: Not applicable
Packing group	: Not applicable
Labels	: Not applicable
Environmentally hazardous	: no

IATA-DGR

UN/ID No.	: Not applicable
Proper shipping name	: Not applicable

Sitagliptin / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
10.0	11.08.2025	24511-00025	Date of first issue: 21.10.2014

Class	: Not applicable
Subsidiary risk	: Not applicable
Packing group	: Not applicable
Labels	: Not applicable
Packing instruction (cargo aircraft)	: Not applicable
Packing instruction (passenger aircraft)	: Not applicable

IMDG-Code

UN number	: Not applicable
Proper shipping name	: Not applicable
Class	: Not applicable
Subsidiary risk	: Not applicable
Packing group	: Not applicable
Labels	: Not applicable
EmS Code	: Not applicable
Marine pollutant	: Not applicable

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations**NZS 5433**

UN number	: Not applicable
Proper shipping name	: Not applicable
Class	: Not applicable
Subsidiary risk	: Not applicable
Packing group	: Not applicable
Labels	: Not applicable
Hazchem Code	: Not applicable

Special precautions for user

Not applicable

Section 15: Regulatory information**Safety, health and environmental regulations/legislation specific for the substance or mixture****HSNO Approval Number**

HSR100425 Pharmaceutical Active Ingredients Group Standard

Tolerable Exposure Limits (TEL)

Not applicable

Environmental Exposure Limits (EEL)

Not applicable

HSW Controls

|| Certified handler certificate not required.
|| Tracking hazardous substance not required.

Sitagliptin / Simvastatin Formulation

Version 10.0	Revision Date: 11.08.2025	SDS Number: 24511-00025	Date of last issue: 06.07.2024 Date of first issue: 21.10.2014
-----------------	------------------------------	----------------------------	---

Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.

The components of this product are reported in the following inventories:

AICS	: not determined
DSL	: not determined
IECSC	: not determined

Section 16: Other information

Revision Date : 11.08.2025

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH	: USA. ACGIH Threshold Limit Values (TLV)
NZ OEL	: New Zealand. Workplace Exposure Standards for Atmospheric Contaminants

ACGIH / TWA	: 8-hour, time-weighted average
NZ OEL / WES-TWA	: Workplace Exposure Standard - Time Weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Develop-

Sitagliptin / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
10.0	11.08.2025	24511-00025	Date of first issue: 21.10.2014

ment; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NZ / EN